Modified natural killer T cells, pharmaceutical compositions and uses thereof
AssigneeFullhope Biomedical Co., Ltd.
InventorsJan-Mou Lee, Chih-Hao Fang, Ya-Fang Cheng, Da-Tsen Wei, Kai-Yuan Jhou
Life of this patent
Estimating the term…
Abstract
The present invention provides modified natural killer T (NKT) cells, pharmaceutical compositions comprising the modified NKT cells and at least one pharmaceutically acceptable carrier or excipient, and uses of the modified NKT cells. Also disclosed herein are methods for enriching NKT cells and generating the modified natural killer T cells.
Claims14
A population of natural killer T (NKT) cells carrying a phenotype of CD3+CD56+CD8+CD1d tetramer−TCR Vα24_Jα18−PD-1+CD25+Foxp3+CTLA-4+LAP+GITR−and PI-16−.
A composition, comprising
- (a) a population of natural killer T cells carrying a phenotype of CD3+CD56+CD8+CD1d tetramer−TCR Vα24_Jα18−PD-1+CD25+Foxp3+CTLA-4+LAP+GITR−and PI-16−;
- and
- (b) a pharmaceutically acceptable carrier or excipient.
A population of natural killer T (NKT) cells carrying a phenotype of CD3+CD56+CD8+CD1 d-tetramer−TCR Vα24_Jα18−GITR−PI-16−CD25+Foxp3+CTLA-4+LAP+PD-1+IL-15Rα−.
Dependencies are inferred from the claim text.